IL15 and acute myeloid leukemia: Delta One T cells (DOTs), an enriched γδT cell product, were modified with CD123.CAR and showed effective AML in vivo control after multiple cell infusions or a single infusion with daily IL15 support, with the latter condition exhibiting an anti-AML effect even after the tumor re-challenge [52].